IP Library Granted Patent US 12,377,192
Granted Patent B2
US 12,377,192 · App. 17/603,448 · Granted Aug 5, 2025

Tissue derived porous matrices and methods for making and using same

Inventors: Christopher M. Nichols (Tacoma, WA); Abigail Phipps (East Brunswick, NJ); Andrew Madans (Jersey City, NJ); Kevin Wu (Morganville, NJ); Evangelia Chnari (Scotch Plains, NJ)
Assignee: Musculoskeletal Transplant Foundation
A61L27/3633A61L15/40A61L15/425A61L27/362A61L27/3687A61L27/54A61L27/56A61L27/58A61L27/60A61M1/915A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,192
App. No.
17/603,448
Granted
Aug 5, 2025
Kind
B2
Abstract

Tissue derived porous matrices for treating wounds are provided, as well as methods for making and using them. The tissue derived porous matrices comprise processed tissue of any of several types, such as dermis, adipose, etc., and have a plurality of interconnected pores which allow fluid flow through the matrices. The tissue derived matrices are biocompatible resorbable matrices which remodel with native tissue and facilitate and enhance cell infiltration and tissue ingrowth into the matrices during the wound healing process, thereby enhancing wound healing and tissue remodeling when implanted into a patient. The tissue derived matrices are useful with reduced or negative pressure wound healing methods and systems, without the need to repeatedly revisit the treatment site and remove previously implanted matrices.

Claims (24)

1. A method for producing a tissue derived porous matrix which is resorbable and has a plurality of interconnected pores which allow fluid flow through the matrix, the method comprising the steps of: obtaining a sample of non-neonatal mammalian tissue selected from dermis, adipose, fascia, and combinations thereof and having a native porosity; reducing the size of the mammalian tissue one or more times; forming or modifying pores; drying the mammalian tissue to produce a dried mammalian tissue having a porous structure; stabilizing the dried mammalian tissue by at least partially crosslinking by contacting the dried mammalian tissue with a crosslinking solution for a period of time, and then removing excess crosslinking solution by performing one or more rinses and at least partially compressing the crosslinked mammalian tissue to separate additional excess crosslinking solution from the crosslinked mammalian tissue, which produces a crosslinked mammalian tissue having a partially collapsed porous structure; and restoring at least a portion of the partially collapsed porous structure by contacting the crosslinked mammalian tissue with an aqueous solvent for a period of time, and then drying the crosslinked mammalian tissue a second time by lyophilizing, which produces a dried, crosslinked mammalian tissue having a porous structure with increased thickness and increased porosity compared to the crosslinked mammalian tissue produced by the stabilizing step, wherein the increased porosity is from about 50% to about 99%.

2. The method of claim 1 , further comprising the step of formulating by mixing, attaching, or otherwise combining the tissue derived porous matrix with one or more additional biocompatible materials or other synthetic or naturally-derived matrices.

3. The method of claim 1 , wherein the step of reducing the size of the mammalian tissue one or more times is performed by cutting, blending, milling, or a combination thereof.

4. The method of claim 1 , further comprising one or more of the following steps:

one or both of delipidating and demineralizing the mammalian tissue;

decellularizing the mammalian tissue;

disinfecting the mammalian tissue;

combining a solvent with the mammalian tissue;

after performing the step of reducing the size of the mammalian tissue at least one time,

placing the mammalian tissue in a container or mold; and

disinfecting the crosslinked tissue.

5. The method of claim 4 , wherein the step of disinfecting the tissue comprises sterilizing the tissue, either before or after the drying step, or both.

6. The method of claim 4 , wherein the step of combining a solvent with the tissue is performed prior to the drying step and the solvent is water, wherein a tissue and water mixture is formed, and wherein the steps of forming or modifying pores and drying the tissue are performed concurrently by lyophilizing the tissue and water mixture.

7. A tissue derived porous matrix produced by the method of claim 1 and comprising a processed tissue which is a three-dimensional scaffold derived from a sample of non-neonatal mammalian tissue selected from dermis, adipose, fascia, and combinations thereof and having a native porosity, wherein the matrix is resorbable, has a plurality of interconnected pores which allow fluid flow through the matrix, and is at least partially cross-linked which stabilizes the matrix and provides a controlled resorption rate after implantation, wherein the tissue derived porous matrix has increased thickness and increased porosity compared to an at least partially crosslinked mammalian tissue which has not been subjected to contacting with an aqueous solvent and drying after crosslinking has been performed, wherein the increased porosity is from about 50% to about 99%, and wherein the tissue derived porous matrix lacks a manifold layer, or lacks a release material layer, or lacks both.

8. The tissue derived porous matrix of claim 7 , wherein when the matrix is implanted, in contact or proximity, with a wound site of a subject, the matrix at least partially degrades, partially remodels with native tissue at the wound site, or both, wherein no portion of the matrix need be removed from the wound site after being positioned with the wound.

9. The tissue derived porous matrix of claim 8 , wherein the matrix has a desired shape and has been lyophilized in a container or mold having the desired shape.

10. The tissue derived porous matrix of claim 7 , wherein when implanted in proximity or contact with a wound site of a subject, fluid flow from the wound site and through the matrix occurs, with or without application of reduced pressure, during healing at the wound site.

11. The tissue derived porous matrix of claim 7 , further comprising one or more endogenous beneficial substances.

12. A biocompatible composition comprising the tissue derived porous matrix of claim 7 and one or more additional biocompatible materials.

13. A wound dressing for treating a wound site comprising:

a porous component comprising the tissue derived porous matrix of claim 7 ; and

a semipermeable barrier component sized and shaped to cover the porous component and

a wound site to be treated with the wound dressing.

14. A method for treating a wound comprising implanting the tissue derived porous matrix of claim 7 , in contact or proximity, with a wound site of a subject, wherein the matrix comprises a tissue having a plurality of interconnected pores which allow fluid flow through the matrix and the matrix is resorbable.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2024
From: NICHOLS, CHRISTOPHER M.; PHIPPS, ABIGAIL; MADANS, ANDREW; WU, KEVIN; CHNARI, EVANGELIA
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 068748/0619 →
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
Continuity (2)
Provisional Application 62845015 · May 8, 2019
Related Publication 20220280693A1 · Sep 8, 2022
References Cited (87)
US 5636643A · Argenta et al. · 1997 [cited by applicant]
US 5645081A · Argenta et al. · 1997 [cited by applicant]
US 8163974B2 · Ambroio et al. · 2012 [cited by applicant]
US 8197806B2 · Girouard et al. · 2012 [cited by applicant]
US 9642937B2 · Zhao et al. · 2017 [cited by applicant]
US 10039633B2 · Ansorge et al. · 2018 [cited by applicant]
US 10213526B2 · Badylak et al. · 2019 [cited by applicant]
US 10869949B2 · Zelen et al. · 2020 [cited by applicant]
US 11638640B2 · Rehnke · 2023 [cited by applicant]
US 11992579B2 · Valmikinathan et al. · 2024 [cited by applicant]
US 20050266390A1 · Ueda et al. · 2005 [cited by examiner]
US 20070299412A1 · Vogel · 2007 [cited by applicant]
US 20110195107A1 · Min et al. · 2011 [cited by applicant]
US 20110251566A1 · Zmnitsky et al. · 2011 [cited by applicant]
US 20120310367A1 · Connor · 2012 [cited by applicant]
US 20140163447A1 · Wieland et al. · 2014 [cited by applicant]
US 20150283287A1 · Agarwal et al. · 2015 [cited by applicant]
US 20150352257A1 · Early · 2015 [cited by examiner]
US 20160051728A1 · Flynn · 2016 [cited by applicant]
US 20160101215A1 · Zhao et al. · 2016 [cited by applicant]
US 20180326120A1 · Grant et al. · 2018 [cited by applicant]
US 20190374683A1 · Badylak et al. · 2019 [cited by applicant]
US 20200000965A1 · Klopotek · 2020 [cited by examiner]
US 20200376160A1 · Xu et al. · 2020 [cited by applicant]
US 20230211048A1 · Xu et al. · 2023 [cited by applicant]
US 20240342341A1 · Valmikinathan et al. · 2024 [cited by applicant]
AU 2020267589 · 2022 [cited by applicant]
CA 3138899 · 2020 [cited by applicant]
CN 106310373 · 2017 [cited by applicant]
CN 106730008 · 2017 [cited by applicant]
CN 106880872 · 2017 [cited by applicant]
DE 10350654 · 2005 [cited by applicant]
EP 3965835 · 2022 [cited by applicant]
EP 3965835B1 · 2024 [cited by applicant]
IL 287906 · 2022 [cited by applicant]
JP 2009504246 · 2009 [cited by applicant]
JP 2016521592 · 2016 [cited by applicant]
JP 2018127490A · 2018 [cited by applicant]
JP 2022531489 · 2022 [cited by applicant]
JP 2022531489A · 2022 [cited by applicant]
KR 20100041027A · 2010 [cited by applicant]
KR 20220018481 · 2022 [cited by applicant]
WO 2004104076 · 2004 [cited by applicant]
WO 2005113656 · 2005 [cited by applicant]
WO 2008020066 · 2008 [cited by applicant]
WO 2014110269 · 2014 [cited by applicant]
WO 2020227601 · 2020 [cited by applicant]
Grabow, N., et al., Artificial Organs 28(11): 971-979 (2004). (Year: 2004). [cited by examiner]
First Examination Report issued on Jan. 16, 2024 by the Canadian Patent Office in connection with corresponding Canadian Patent Application No. 3,138,899. [cited by applicant]
International Search Report issued on Jul. 31, 2020 for corresponding International Patent Application No. PCT/US2020/032022. [cited by applicant]
Written Opinion of the International Search Authority issued on Jul. 31, 2020 for corresponding International Patent Application No. PCT/US2020/032022. [cited by applicant]
International Preliminary Report on Patentability for corresponding International Patent Application No. PCT/US2020/032022. [cited by applicant]
Choi, et al., “Full-thickness skin wound healing using human placenta-derived extracellular matrix containing bioactive molecules”, Tissue Engineering Part A, 2013, vol. 19, pp. 3290339. [cited by applicant]
EP Communication pursuant to Article 94(3) EPC issued on Sep. 26, 2022 for corresponding European Patent Application No. 20728625.3. [cited by applicant]
Second Written Submissions filed Feb. 16, 2024, in advance of Oral Hearing for May 16, 2024, in the corresponding European Patent Application No. 20728625.3. [cited by applicant]
Office Action issued by the Israeli Patent Office on Feb. 21, 2024 in connection with corresponding Israeli Patent Application No. 287906. [cited by applicant]
English translation of Office Action issued by the Israeli Patent Office on Feb. 21, 2024 in connection with corresponding Israeli Patent Application No. 287906. [cited by applicant]
Second Examination Report issued on Feb. 15, 2023 by the Australian Patent Office for Australian Patent Application No. 2020267589. [cited by applicant]
Third Australian Examination Report issued on Sep. 28, 2023 for corresponding Australian Patent Application No. 2020267589. [cited by applicant]
First Office Action issued on Feb. 7, 2024 by the Japanese Patent Office for corresponding Japanese Patent Application No. 2021-566098. [cited by applicant]
EP Communication regarding oral proceedings issued on Nov. 27, 2023 for corresponding European Patent Application No. 20728625.3. [cited by applicant]
EP Communication regarding summons for oral proceedings, issued on Apr. 19, 2023 for corresponding European Patent Application No. 20728625.3. [cited by applicant]
EP Communication regarding oral proceedings issued on Dec. 8, 2023 for corresponding European Patent Application No. 20728625.3. [cited by applicant]
EP Communication regarding summons for new oral proceedings issued on Dec. 21, 2023 for corresponding European Patent Application No. 20728625.3. [cited by applicant]
Notice of Acceptance issued on Dec. 13, 2023 for corresponding Australian Patent Application No. 2020267589. [cited by applicant]
Machine Translation from German of DE 10350654 A1 (Abstract, Description, Claims), filed Oct. 29, 2003, published Jun. 2, 2005. [cited by applicant]
Meyer M., “Processing of collagen based biomaterials and the resulting materials properties”, Meyer BioMed Eng OnLine, 2019, vol. 18, pp. 1-74. [cited by applicant]
Third Examination Report issued Sep. 28, 2023 for corresponding Australian Patent Appln No. 2020267589 (OEE Work Product for PPH). [cited by applicant]
First Examination Report for Australian Patent Application No. 2020267589, issued on Dec. 22, 2022. [cited by applicant]
Australian Patent No. 2020267589, granted on Apr. 18, 2024 for corresponding Australian Patent Application No. 2020267589, previously cited . . . . [cited by applicant]
English Translation Office Action issued on Jun. 7, 2024 for corresponding Japanese Patent Application No. 2021-566098. [cited by applicant]
Office Action issued on Jun. 7, 2024 for corresponding Japanese Patent Application No. 2021-566098. [cited by applicant]
English Translation Korean Intellectual Property Office, Notice of Preliminary Rejection issued on Jun. 4, 2024, for corresponding Korean Patent Application No. 10-2021-7038783. [cited by applicant]
Korean Intellectual Property Office, Notice of Preliminary Rejection issued on Jun. 4, 2024, for corresponding Korean Patent Application No. 10-2021-7038783. [cited by applicant]
Provision of minutes in accordance with Rule 124(4) EPC, Part 1, in connection with corresponding European Patent Application No. 20728625.3. [cited by applicant]
Provision of minutes in accordance with Rule 124(4) EPC, Part 2, in connection with corresponding European Patent Application No. 20728625.3. [cited by applicant]
Communication under Rule 71(3) EPC issued by the European Patent Office on Jun. 11, 2024 in connection with corresponding European Patent Application No. 20728653.3. [cited by applicant]
Translation of Notice of Acceptance issued on Oct. 7, 2024 for corresponding Israeli Patent Application No. 287906. [cited by applicant]
Notice of Acceptance issued on Oct. 7, 2024 for corresponding Israeli Patent Application No. 287906. [cited by applicant]
Communication of the date of registration of unitary effect pursuant to Rule 7(1) UPR, issued on Oct. 23, 2024 for corresponding European Patent Application No. 20728625. [cited by applicant]
Notice of Final Rejection issued on Oct. 31, 2024 for corresponding Korean Patent Application No. 10-2021-7038783. [cited by applicant]
English translation of Notice of Final Rejection issued on Oct. 31, 2024 for corresponding Korean Patent Application No. 10-2021-7038783. [cited by applicant]
Certificate of Patent Grant for JP Pat. No. 7551632 (Japanese language), issued Sep. 6, 2024, for co-owned corresponding Japanese Pat. Appln. No. 2021-0377815. [cited by applicant]
English Translation of Certificate of Patent Grant for JP Pat. No. 7551632 (Japanese language), issued Sep. 6, 2024, for co-owned corresponding Japanese Pat. Appln. No. 2021-0377815. [cited by applicant]
English translation of Decision to Grant. Issued by Japanese Patent Office on Aug. 9, 2024 for corresponding Japanese Patent Application No. 2021-566098. [cited by applicant]
Decision to Grant. Issued by Japanese Patent Office on Aug. 9, 2024 for corresponding Japanese Patent Application No. 2021-566098. [cited by applicant]
Notice of Allowance issued by the Canadian Patent Office on Jun. 10, 2024 for corresponding Canadian Patent Application No. 3,138,899. [cited by applicant]